| Literature DB >> 30684591 |
Minjiang Chen1, Aiwu Mao2, Min Xu1, Qiaoyou Weng1, Jianting Mao1, Jiansong Ji3.
Abstract
Cancer is a genetic disease stemming from cumulative genetic/epigenetic aberrations. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9-mediated genome editing technology has been extensively applied in various cell types and organisms, both in vitro and in vivo, for efficient gene disruption and gene modification. CRISPR-Cas9 has shown great promise for the treatment of cancer. However, despite its advantages and tremendous potential, numerous challenges, such as fitness of edited cells, editing efficiency, delivery methods and potential off-target effects, remain to be solved for completely clinical application. Here, we present the potential applications and recent advances of CRISPR-Cas9 in cancer therapy, and discuss the challenges that might be encountered in clinical applications.Entities:
Keywords: CRISPR-Cas9; Cancer; Gene editing; Immunotherapy; Oncolytic virotherapy
Mesh:
Year: 2019 PMID: 30684591 DOI: 10.1016/j.canlet.2019.01.017
Source DB: PubMed Journal: Cancer Lett ISSN: 0304-3835 Impact factor: 8.679